We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Boston Scientific (BSX – Research Report) with bullish ...

The findings from Briumvi’s developer TG Therapeutics, were presented at the 2024 European Committee for Treatment and ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...

TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted in an ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...